Loading…
Employees: 231
Size ProKidney (PROK) is a United States Health Care company (Biotechnology) with a market value of $345M, the 2994th largest of 3,117 United States companies the cockpit tracks. Shares closed at $1.14 on 6 Nov 2026.
Performance Over six months the shares fell 38.7%, against -23.1% for the median peer and -1.1% for the United States market (cap-weighted) — 5th lowest of 18 in its peer set.
Growth Revenue grew 55.2% over the last twelve months (peer median -26.9%); the operating margin is -21,664.5% (peer median -385.3%).
Valuation It trades at 1,556.3× enterprise value to sales against a peer median of 11.6× (2nd most expensive of 16).
Capital Return on invested capital runs 76.1 points below its cost of capital (14.2% WACC).
Next results Next results expected around 16 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $818,000 | $893,000 | $76,000 | $0 | $0 |
| Revenue growth | — | +1,075% | — | — | — |
| Gross profit | -$4.91M | -$4.83M | -$4.26M | -$3.17M | -$3.04M |
| EBITDA | -$171M | -$159M | -$174M | -$148M | -$150M |
| Net income | -$84.2M | -$69.0M | -$61.2M | -$35.5M | -$108M |
| Free cash flow | -$160M | -$135M | -$156M | -$124M | -$78.9M |
| Capital expenditure | $18.6M | $15.2M | $29.5M | $34.2M | $1.85M |
| Total debt | $3.52M | $4.04M | $3.24M | $4.41M | $2.40M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PROK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -31.3% | -13.7% | 5th lowest of 20 |
| 6-month return | -38.7% | -23.1% | 5th lowest of 18 |
| Distance from 52-week high | -61.4% | -53.8% | 8th lowest of 20 |
| Revenue growth (TTM) | +55.2% | -26.9% | 4th highest of 15 |
| Operating margin | -21,664.5% | -385.3% | 2nd lowest of 16 |
| EV / Sales | 1,556.3× | 11.6× | 2nd most expensive of 16 |
| ROIC minus cost of capital | -76.1 pp | -44.3 pp | 5th highest of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | 1,556.3× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 5.1× | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | 392.1× | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | 14.4× | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 1.2× | 5.6% | +19.1% |
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | n/a | n/a | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 2.7× | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | 22.8× | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $330M | -32% | -100% | n/a | n/a | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $328M | -57% | n/a | -57% | 4.8× | n/a | n/a |
| Zhejiang Laifual Drive 3952.HK | Hong Kong | $363M | n/a | +142% | -11% | 7.1× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $364M | -23% | -55% | -729,281% | 7,653.4× | n/a | n/a |
| Surrozen SRZN | United States | $364M | -35% | -9% | -385% | 23.3× | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $325M | n/a | +395% | -173% | 9.9× | n/a | n/a |
| TransThera Sciences (Nanjing) 2617.HK | Hong Kong | $323M | -83% | n/a | -751% | 36.4× | n/a | n/a |
| Agenus AGEN | United States | $323M | +87% | +30% | 27% | 4.4× | n/a | n/a |
| G2GBIO 456160.KS | South Korea | $370M | -65% | -45% | -2,884% | 775.0× | n/a | n/a |
| Galectin Therapeutics GALT | United States | $317M | +50% | n/a | n/a | n/a | n/a | n/a |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |
| X4 Pharmaceuticals XFOR | United States | $315M | -28% | -52% | -555% | 11.6× | n/a | n/a |